Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

EYEN

Eyenovia Inc

May 08 • 12:05PM ET

0.8572

Dollar change +0.0428
Percentage change 5.26	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO IWC VTWG BTEC VTHR URTY

Index	RUT	P/E	-	EPS (ttm)	-0.67	Insider Own	17.48%	Shs Outstand	45.55M	Perf Week	-6.32%
Market Cap	43.68M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	1.89%	Shs Float	42.05M	Perf Month	39.36%
Income	-27.26M	PEG	-	EPS next Q	-0.23	Inst Own	24.49%	Short Float	12.79%	Perf Quarter	-51.43%
Sales	0.00M	P/S	-	EPS this Y	-34.47%	Inst Trans	-28.80%	Short Ratio	3.85	Perf Half Y	-34.31%
Book/sh	0.20	P/B	4.34	EPS next Y	-1.17%	ROA	-91.15%	Short Interest	5.38M	Perf Year	-80.61%
Cash/sh	0.29	P/C	2.94	EPS next 5Y	-	ROE	-207.83%	52W Range	0.50 - 4.88	Perf YTD	-58.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.26%	ROI	-141.62%	52W High	-82.43%	Beta	1.73
Dividend TTM	-	Quick Ratio	1.71	Sales past 5Y	100.00%	Gross Margin	-28100.77%	52W Low	71.10%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	1.73	EPS Y/Y TTM	19.42%	Oper. Margin	-670885.82%	RSI (14)	51.05	Volatility	20.59% 17.40%
Employees	57	Debt/Eq	1.79	Sales Y/Y TTM	-99.99%	Profit Margin	-719859.94%	Recom	1.00	Target Price	8.25
Option/Short	Yes / Yes	LT Debt/Eq	1.14	EPS Q/Q	-5.22%	Payout	-	Rel Volume	0.66	Prev Close	0.81
Sales Surprise	947.33%	EPS Surprise	-3.63%	Sales Q/Q	-	Earnings	Mar 18 AMC	Avg Volume	1.40M	Price	0.86
SMA20	27.88%	SMA50	-23.40%	SMA200	-44.45%	Trades		Volume	395,365	Change	5.26%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-21	Initiated	Northland Capital	Outperform	$10
Feb-03-20	Downgrade	Oppenheimer	Outperform → Perform

Apr-25-24 07:00AM	Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension (GlobeNewswire) +21.90%
Apr-09-24 09:29AM	Eyenovia (EYEN) Down 18% on Disappointing Corporate Update (Zacks) -15.73%
Apr-08-24 07:00AM	Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities (GlobeNewswire) -17.99%
Apr-03-24 07:00AM	Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings (GlobeNewswire) -6.63%
Mar-27-24 11:28AM	NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:57AM	Loading…
09:57AM	Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:50AM	Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -23.20%
06:41AM	Q4 2023 Eyenovia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 08:53PM	EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:20PM	Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-24 07:00AM	NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals (GlobeNewswire)
Mar-11-24 07:00AM	Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th (GlobeNewswire)
Mar-05-24 12:59PM	Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation (Benzinga) -22.81%
08:00AM	Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery (GlobeNewswire)
06:21PM	Loading…
Mar-04-24 06:21PM	UPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says (Reuters)
06:06PM	US FDA approves Eyenovia's eye drug, Formosa Pharma says (Reuters)
Feb-13-24 07:00AM	Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility (GlobeNewswire) -5.76%
Jan-26-24 09:22AM	Formosa, fresh from Eyenovia deal, sells Brazilian rights to near-approval eye drug (FierceBiotech.com)
Jan-16-24 07:00AM	Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada (GlobeNewswire) -7.51%
Dec-15-23 08:17AM	7 Promising Penny Stocks With the Potential to Defy Expectations (InvestorPlace)
Nov-14-23 10:38AM	Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.04%
Nov-13-23 04:05PM	Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:00AM	Eyenovia to Report Third Quarter 2023 Results on Monday, November 13 (GlobeNewswire) -8.74%
Nov-02-23 07:00AM	Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey) +6.48%
07:00AM	Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO's 51st Annual Continuing Education (ACE) Program (GlobeNewswire)
Oct-09-23 07:00AM	Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet (GlobeNewswire)
Sep-21-23 08:00AM	Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference (GlobeNewswire)
Sep-07-23 08:00AM	Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
06:47PM	Loading…
Aug-24-23 06:47PM	Eyenovia Announces $12 Million Registered Direct Offering (GlobeNewswire)
Aug-16-23 06:00AM	Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals (GlobeNewswire) -6.44%
Aug-14-23 09:05AM	Eyenovia, Inc. (NASDAQ:EYEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:08AM	Q2 2023 Eyenovia Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:05PM	Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-09-23 08:00AM	Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-07-23 08:00AM	Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10 (GlobeNewswire)
Aug-03-23 08:00AM	Eyenovia Announces First Commercial Sale of Mydcombi (GlobeNewswire)
Jun-26-23 08:00AM	Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes (GlobeNewswire) -6.75%
Jun-06-23 09:00AM	Eyenovia Expands Its US Manufacturing Capabilities (ACCESSWIRE)
Jun-01-23 08:00AM	Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023 (GlobeNewswire) +9.15%
May-12-23 06:04AM	Q1 2023 Eyenovia Inc Earnings Call (Thomson Reuters StreetEvents) -15.20%
May-11-23 04:05PM	Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -5.77%
May-08-23 04:39PM	Eyenovia Shares Dip Despite FDA Approving Its First Product (Benzinga)
08:17AM	UPDATE 2-US FDA approves Eyenovia's pupil-dilating spray (Reuters)
08:02AM	US FDA approves Eyenovia's pupil-dilating spray (Reuters)
08:00AM	Eyenovia Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Companys Proprietary Optejet® Device Platform (GlobeNewswire)
02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com)
May-04-23 08:00AM	Eyenovia to Report First Quarter 2023 Results on Thursday, May 11 (GlobeNewswire) -12.87%
Apr-24-23 08:00AM	Eyenovia Announces Poster Presentation at ARVO 2023 (GlobeNewswire)
Apr-05-23 07:46PM	Eyenovia, Inc. (NASDAQ:EYEN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 04:05PM	Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-23 08:00AM	Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30 (GlobeNewswire) +9.16%
Feb-28-23 04:05PM	Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White Houses Office of Public Engagement (GlobeNewswire)
Feb-22-23 06:08AM	Eyenovia (NASDAQ:EYEN) shareholders have endured a 69% loss from investing in the stock five years ago (Simply Wall St.) +7.77%
Feb-15-23 09:51AM	Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals (GlobeNewswire) +11.01%
Jan-12-23 12:47PM	Eyenovia's Optejet Shows Lower Proinflammatory Cytokines Levels, Chemokines Than Standard Drops (Benzinga) +17.02%
08:00AM	Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops (GlobeNewswire)
Dec-20-22 08:00AM	Eyenovia Announces Participation at the 2023 International Consumer Electronics Show (GlobeNewswire)
Dec-13-22 08:00AM	Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi for In-Office Pupil Dilation (GlobeNewswire) +7.51%
Dec-08-22 08:00AM	Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President (GlobeNewswire)
Nov-29-22 08:00AM	Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund (GlobeNewswire) +6.49%
Nov-23-22 04:05PM	Eyenovia to Present at Upcoming BTIG Ophthalmology Day (GlobeNewswire) +5.59%
Nov-13-22 07:04AM	Eyenovia Third Quarter 2022 Earnings: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021) (Simply Wall St.)
Nov-10-22 04:05PM	Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 08:00AM	Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10 (GlobeNewswire)
Oct-21-22 08:00AM	Eyenovia to Present at the American Academy of Optometrys Annual Meeting (GlobeNewswire)
Oct-20-22 08:00AM	Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia (GlobeNewswire) -5.20%
Oct-05-22 02:50PM	HC Wainwright Initiates This Eye-Focused Stock With Almost 400% Upside (Benzinga) +13.02%
Sep-30-22 08:00AM	Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr. (GlobeNewswire)
Sep-07-22 08:00AM	Eyenovia to Present at Upcoming Healthcare Conferences (GlobeNewswire) +7.18%
Sep-06-22 08:00AM	Eyenovia to Participate in Multiple Medical Meetings in September (GlobeNewswire) +10.17%
Aug-10-22 04:05PM	Eyenovia Reports Second Quarter 2022 Financial Results (GlobeNewswire) +5.42%
Aug-04-22 08:00AM	Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10 (GlobeNewswire)
Jul-27-22 08:00AM	Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member (GlobeNewswire)
Jul-18-22 08:00AM	Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations (GlobeNewswire)
Jul-07-22 08:00AM	Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors (GlobeNewswire)
Jul-06-22 08:00AM	Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China (GlobeNewswire)
Jun-29-22 08:53AM	Eyenovia (NASDAQ:EYEN) shareholders have endured a 65% loss from investing in the stock a year ago (Simply Wall St.)
Jun-09-22 10:09AM	UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders (GlobeNewswire) -5.19%
08:00AM	Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders (GlobeNewswire)
Jun-07-22 08:00AM	Eyenovia Announces Planned Chief Executive Officer Transition (GlobeNewswire)
May-15-22 08:06AM	Is Eyenovia (NASDAQ:EYEN) A Risky Investment? (Simply Wall St.)
May-12-22 04:05PM	Eyenovia Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 08:00AM	Eyenovia to Report First Quarter 2022 Results on Thursday, May 12 (GlobeNewswire)
Apr-20-22 08:00AM	Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022 (GlobeNewswire)
Apr-19-22 08:00AM	Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire)
Apr-03-22 01:46PM	News Flash: One Analyst Just Made A Stunning Upgrade To Their Eyenovia, Inc. (NASDAQ:EYEN) Forecasts (Simply Wall St.)
Mar-31-22 01:17PM	Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts (Simply Wall St.)
Mar-28-22 04:05PM	Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-21-22 08:00AM	Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28 (GlobeNewswire)
Mar-15-22 08:00AM	Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions (GlobeNewswire)
Mar-04-22 09:07AM	Eyenovia Raises 15M Via Equity To Advance MydCombi Program (Benzinga)
07:00AM	Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd. (GlobeNewswire)
Feb-13-22 06:29AM	Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN) (Simply Wall St.)
Feb-08-22 08:00AM	Eyenovia Concludes Type A Meeting with FDA Related to MydCombi NDA Resubmission (GlobeNewswire)
Feb-07-22 08:30AM	Eyenovia Announces Changes to Board of Directors (GlobeNewswire)
Dec-10-21 05:46AM	Eyenovia (NASDAQ:EYEN) investors are sitting on a loss of 12% if they invested a year ago (Simply Wall St.)
Nov-17-21 12:00PM	Notable Eyenovia Insider Makes $360K Buy (Benzinga)
Nov-10-21 06:45PM	Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grant Stuart M.	10% Owner	Mar 28 '24	Buy	0.98	100,000	98,000	5,430,715	Mar 28 03:50 PM
Grant Stuart M.	10% Owner	Mar 19 '24	Buy	1.23	50,000	61,500	5,330,715	Mar 20 05:44 PM
Grant Stuart M.	10% Owner	Mar 08 '24	Buy	1.58	10,717	16,911	5,280,715	Mar 11 08:11 AM
Rowe Michael M	Chief Executive Officer	Dec 04 '23	Buy	1.36	4,890	6,650	32,927	Dec 05 04:54 PM
Strahlman Ellen R	Director	Sep 29 '23	Buy	1.68	4,820	8,098	75,113	Oct 02 10:04 AM
Rowe Michael M	Chief Executive Officer	Sep 19 '23	Buy	1.66	1,400	2,324	28,037	Sep 19 05:17 PM
Rowe Michael M	Chief Executive Officer	Sep 15 '23	Buy	1.75	1,137	1,990	26,637	Sep 19 05:17 PM
Grant Stuart M.	10% Owner	Aug 17 '23	Buy	1.87	30,000	56,100	5,269,998	Aug 17 03:16 PM
Grant Stuart M.	10% Owner	Aug 16 '23	Buy	1.91	45,000	85,815	5,239,998	Aug 17 03:16 PM
GANDOLFO JOHN P	Chief Financial Officer	May 31 '23	Buy	2.79	2,000	5,580	8,000	May 31 06:31 PM
MATHER CHARLES E IV	Director	May 26 '23	Buy	2.49	3,000	7,470	77,544	May 30 10:13 AM
Kern Bren	Chief Operating Officer	May 26 '23	Buy	2.73	2,500	6,825	2,500	May 31 10:48 AM
Grant Stuart M.	10% Owner	May 25 '23	Buy	2.65	88,247	233,855	5,194,998	May 26 12:55 PM
Strahlman Ellen R	Director	May 23 '23	Buy	3.10	10,000	30,976	53,052	May 25 04:45 PM

Open in Screener

ECOR

ElectroCore Inc

May 08 • 12:00PM ET

7.39

Dollar change +0.37
Percentage change 5.27	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-3.56	Insider Own	16.52%	Shs Outstand	6.00M	Perf Week	22.35%
Market Cap	44.34M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.00%	Shs Float	5.01M	Perf Month	22.96%
Income	-18.83M	PEG	-	EPS next Q	-0.59	Inst Own	16.60%	Short Float	0.18%	Perf Quarter	2.07%
Sales	16.03M	P/S	2.77	EPS this Y	47.19%	Inst Trans	-11.20%	Short Ratio	0.83	Perf Half Y	20.55%
Book/sh	1.24	P/B	5.96	EPS next Y	44.35%	ROA	-90.88%	Short Interest	0.01M	Perf Year	22.15%
Cash/sh	1.76	P/C	4.19	EPS next 5Y	-	ROE	-153.57%	52W Range	3.83 - 8.08	Perf YTD	24.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.11%	ROI	-236.04%	52W High	-8.54%	Beta	0.61
Dividend TTM	-	Quick Ratio	1.49	Sales past 5Y	77.42%	Gross Margin	82.51%	52W Low	93.03%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	1.76	EPS Y/Y TTM	24.11%	Oper. Margin	-117.50%	RSI (14)	73.18	Volatility	8.33% 7.40%
Employees	68	Debt/Eq	0.08	Sales Y/Y TTM	86.57%	Profit Margin	-117.49%	Recom	1.00	Target Price	23.10
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	50.07%	Payout	-	Rel Volume	5.05	Prev Close	7.02
Sales Surprise	3.14%	EPS Surprise	-3.04%	Sales Q/Q	102.77%	Earnings	May 08 AMC	Avg Volume	10.64K	Price	7.39
SMA20	24.91%	SMA50	18.76%	SMA200	24.42%	Trades		Volume	22,568	Change	5.27%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-20	Upgrade	BTIG Research	Neutral → Buy	$3.50
Nov-14-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Resumed	Cantor Fitzgerald	Neutral	$9
May-30-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-15-19	Downgrade	BTIG Research	Buy → Neutral
May-09-19	Initiated	Noble Capital Markets	Outperform
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight

May-03-24 04:05PM	electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-24 08:04AM	electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire)
Apr-30-24 08:00AM	Truvaga Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion (GlobeNewswire) +9.46%
Apr-08-24 08:30AM	electroCore Announces the Launch of Truvaga Plus for General Wellness (GlobeNewswire)
Apr-02-24 08:00AM	electroCore Expands Intellectual Property Portfolio (GlobeNewswire)
02:15PM	Loading…
Mar-16-24 02:15PM	electroCore, Inc. (NASDAQ:ECOR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:19AM	Q4 2023 electroCore, Inc. Earnings Call (Thomson Reuters StreetEvents) -5.58%
Mar-13-24 05:25PM	ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	electroCore Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 08:00AM	electroCore to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.05%
Mar-05-24 04:05PM	electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-06-24 08:00AM	electroCore Expands Intellectual Property Portfolio (GlobeNewswire)
Jan-09-24 08:00AM	electroCore Expands Intellectual Property Portfolio (GlobeNewswire)
Dec-26-23 08:00AM	electroCore Expands Intellectual Property Portfolio (GlobeNewswire)
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey)
08:00AM	Loading…
Dec-12-23 08:00AM	electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology (GlobeNewswire)
Nov-15-23 08:15AM	Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023 (GlobeNewswire) +7.80%
Nov-09-23 01:17PM	electroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:29PM	electroCore Inc (ECOR) Reports Substantial Sales Growth in Q3 2023 (GuruFocus.com)
04:01PM	electroCore Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 08:00AM	electroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire) -6.20%
Oct-24-23 08:00AM	Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting (GlobeNewswire)
Oct-17-23 08:00AM	electroCore Announces Two-Year Extension of gammaCore Device Listing in the NHS Supply Chain Catalogue (GlobeNewswire)
Oct-11-23 08:00AM	electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology (GlobeNewswire)
Oct-10-23 08:00AM	Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress (GlobeNewswire) -5.11%
Oct-09-23 08:00AM	electroCore to Announce Third Quarter Financial Results on Wednesday, November 8 (GlobeNewswire)
Oct-05-23 08:00AM	electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference (GlobeNewswire)
Sep-27-23 08:00AM	gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD) (GlobeNewswire)
Sep-26-23 08:00AM	electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology (GlobeNewswire)
Sep-25-23 08:30AM	iAccess Alpha Best Ideas from the Buyside Virtual Conference - Sep 26th-27th 2023 (ACCESSWIRE)
08:00AM	Loading…
08:00AM	electroCore to Participate in the LD Micro Main Event XVI Conference (GlobeNewswire)
Sep-21-23 08:00AM	electroCore to Present at iAccess Alphas Top 10 Best Ideas from the Buyside Virtual Conference (GlobeNewswire)
Sep-07-23 08:00AM	electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-23-23 08:00AM	electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering (GlobeNewswire)
Aug-11-23 01:41PM	electroCore, Inc. (NASDAQ:ECOR) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:46AM	ECOR: 2Q:23 Revenues Impress (Zacks)
Aug-10-23 07:39AM	Q2 2023 electroCore, Inc. Earnings Call (Thomson Reuters StreetEvents) -8.84%
Aug-09-23 04:05PM	electroCore Announces Second Quarter 2023 Financial Results (GlobeNewswire) -10.10%
Aug-04-23 07:14AM	Daily Vickers Top Buyers & Sellers for 08/04/2023 (Argus Research)
Aug-01-23 08:00AM	electroCore to Announce Second Quarter Financial Results on Wednesday, August 9 (GlobeNewswire)
Jul-31-23 09:29AM	electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules (GlobeNewswire)
Jul-25-23 08:00AM	gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD) (GlobeNewswire) -7.20%
Jul-18-23 08:00AM	electroCore Expands Intellectual Patent Portfolio for nVNS Technology (GlobeNewswire)
Jul-17-23 06:03AM	ECOR: Adding Reliefband to the Portfolio (Zacks Small Cap Research)
Jul-13-23 08:00AM	electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC (GlobeNewswire)
Jul-11-23 08:00AM	electroCore Provides Select Second Quarter 2023 Financial Guidance (GlobeNewswire)
Jul-06-23 08:00AM	gammaCore Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms (GlobeNewswire) +6.35%
Jun-27-23 08:00AM	TAC-STIM Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project (GlobeNewswire)
Jun-14-23 08:00AM	electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC (GlobeNewswire)
Jun-13-23 08:00AM	electroCore Announces Poster to be Presented at the American Headache Societys 65th Annual Scientific Meeting (GlobeNewswire) +7.77%
May-26-23 04:01PM	electroCore, Inc. Announces Departure of JP Errico from the Board of Directors (GlobeNewswire) -5.53%
May-23-23 08:00AM	electroCore to Participate at 13th Annual LD Micro Invitational XIII (GlobeNewswire)
May-04-23 06:33AM	ECOR: Getting A BOOST from New Initiatives (Zacks Small Cap Research) -5.00%
May-03-23 04:01PM	electroCore Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-01-23 04:01PM	electroCore to Participate at Annual Aegis Virtual Conference (GlobeNewswire)
Apr-26-23 08:00AM	National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore (nVNS) in Patients with Opioid Use Disorders (GlobeNewswire)
Apr-24-23 08:00AM	Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning (GlobeNewswire)
Apr-19-23 08:00AM	electroCore to Announce First Quarter Financial Results on Wednesday, May 3 (GlobeNewswire)
Apr-17-23 08:00AM	electroCore Provides Select First Quarter 2023 Financial Guidance (GlobeNewswire) +9.51%
Apr-12-23 08:00AM	electroCore Expands Intellectual Patent Portfolio for nVNS Technology (GlobeNewswire)
Apr-11-23 08:00AM	electroCore Announces Remittance of Annual License Fee from Teijin for Certain Exclusive Rights in Japan (GlobeNewswire)
Apr-06-23 08:00AM	electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa (GlobeNewswire)
Apr-04-23 08:00AM	electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute (GlobeNewswire)
Mar-23-23 08:00AM	electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury (GlobeNewswire) +17.10%
Mar-21-23 08:00AM	electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study (GlobeNewswire) +6.46%
Mar-14-23 08:30AM	electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank (GlobeNewswire)
Mar-13-23 08:00AM	electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting (GlobeNewswire)
Mar-10-23 02:25AM	electroCore, Inc. (NASDAQ:ECOR) Q4 2022 Earnings Call Transcript (Insider Monkey) -5.76%
Mar-09-23 11:48AM	ECOR: 2023 Guidance Propelled by New Products (Zacks Small Cap Research) +9.47%
08:00AM	electroCore to Participate at 35th Annual Roth Conference (GlobeNewswire)
Mar-08-23 04:05PM	electroCore Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +6.58%
Mar-07-23 08:00AM	electroCore Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Mar-01-23 08:00AM	electroCore to Announce Fourth Quarter and Year Ended December 31, 2022 Financial Results on Wednesday, March 8 (GlobeNewswire) -6.57%
Feb-21-23 08:00AM	electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa (GlobeNewswire) -12.03%
Feb-16-23 08:00AM	electroCore Expands Intellectual Patent Portfolio for nVNS Technology (GlobeNewswire)
Feb-15-23 08:00AM	electroCore Completes Sale of New Jersey Tax Benefits (GlobeNewswire)
07:01AM	Daily Vickers Top Insider Picks for 02/15/2023 (Argus Research)
Feb-14-23 10:30AM	electroCore Announces Reverse Stock Split (GlobeNewswire) -19.89%
06:23AM	Daily Vickers Top Insider Picks for 02/14/2023 (Argus Research)
Feb-13-23 07:30AM	Daily Vickers Top Insider Picks for 02/13/2023 (Argus Research)
Feb-10-23 06:42AM	Daily Vickers Top Insider Picks for 02/10/2023 (Argus Research)
Feb-09-23 06:51AM	Daily Vickers Top Insider Picks for 02/09/2023 (Argus Research)
Feb-08-23 06:45AM	Daily Vickers Top Insider Picks for 02/08/2023 (Argus Research)
Feb-07-23 06:46AM	Daily Vickers Top Insider Picks for 02/07/2023 (Argus Research)
Feb-06-23 06:56AM	Daily Vickers Top Insider Picks for 02/06/2023 (Argus Research)
Feb-03-23 06:32AM	Daily Vickers Top Insider Picks for 02/03/2023 (Argus Research)
06:30AM	ECOR: Commercial Strength Drives 4Q (Zacks Small Cap Research)
Feb-02-23 06:43AM	Daily Vickers Top Insider Picks for 02/02/2023 (Argus Research) +6.91%
Feb-01-23 06:14AM	Daily Vickers Top Insider Picks for 02/01/2023 (Argus Research)
Jan-31-23 06:50AM	Daily Vickers Top Insider Picks for 01/31/2023 (Argus Research)
Jan-30-23 06:42AM	Daily Vickers Top Insider Picks for 01/30/2023 (Argus Research)
Jan-27-23 07:00AM	Daily Vickers Top Insider Picks for 01/27/2023 (Argus Research)
Jan-26-23 06:44AM	Daily Vickers Top Insider Picks for 01/26/2023 (Argus Research)
Jan-25-23 06:39AM	Daily Vickers Top Insider Picks for 01/25/2023 (Argus Research)
Jan-24-23 06:48AM	Daily Vickers Top Insider Picks for 01/24/2023 (Argus Research)
Jan-23-23 06:58AM	Daily Vickers Top Insider Picks for 01/23/2023 (Argus Research)
Jan-20-23 06:55AM	Daily Vickers Top Insider Picks for 01/20/2023 (Argus Research)
Jan-19-23 06:43AM	Daily Vickers Top Insider Picks for 01/19/2023 (Argus Research) +5.20%
Jan-18-23 06:28AM	Daily Vickers Top Insider Picks for 01/18/2023 (Argus Research) -8.03%
Jan-17-23 08:00AM	electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update (GlobeNewswire) +25.34%

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goldberger Daniel S	Chief Executive Officer	Sep 15 '23	Buy	5.55	1,500	8,332	136,060	Sep 19 08:30 AM
Goldberger Daniel S	Chief Executive Officer	Aug 02 '23	Buy	4.35	50,991	221,811	84,560	Aug 03 03:31 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

EYEN

Eyenovia Inc

ECOR

ElectroCore Inc

Upgrade your FINVIZ experience